Search Results - "Mirolubova, J."

Aza maintenance after consolidation increase RFS in MRDve+ low and not in intermediate risk AML patients by Girshova, L., Budaeva, I., Zaytsev, D., Chitanava, T., Rogovaia, I., Badaev, R., Bogdanov, K., Nikulina, T., Mirolubova, J., Motorin, D., Alexeeva, J., Zaritskey, A.

Get full text

OP-28 - Aza maintenance after consolidation increase RFS in MRDve+ low and not in intermediate risk AML patients by Girshova, L., Budaeva, I., Zaytsev, D., Chitanava, T., Rogovaia, I., Badaev, R., Bogdanov, K., Nikulina, T., Mirolubova, J., Motorin, D., Alexeeva, J., Zaritskey, A.

Get full text

Gemtuzumab ozogamicin in the treatment of critically ill patients with refractory acute myeloid leukemia by Zaytsev, D., Girshova, L., Ivanov, V., Budaeva, I., Motorin, D., Badaev, R., Bogdanov, K., Mirolubova, J., Nikulina, T., Chitanava, T., Alexeeva, J., Zaritskey, A.

Get full text

PP-71 - Gemtuzumab ozogamicin in the treatment of critically ill patients with refractory acute myeloid leukemia by Zaytsev, D., Girshova, L., Ivanov, V., Budaeva, I., Motorin, D., Badaev, R., Bogdanov, K., Mirolubova, J., Nikulina, T., Chitanava, T., Alexeeva, J., Zaritskey, A.

Get full text